Loading...
Market
What will be the outcome of Marea Therapeutics' Phase 1 clinical trial?
3
Resolution / Starting Odds
Positive results • 50%
Negative results • 50%
Clinical trial results, company announcements
Story
Third Rock-backed Marea Therapeutics Launches with $190M to Tackle Cardiometabolic Diseases Targeting ANGPTL4
Jun 18, 2024, 11:49 AM
Marea Therapeutics has launched with $190 million in funding to develop new treatments for cardiometabolic diseases. The biotech company, which focuses on leveraging large-scale human genetics and adipose biology, aims to address the lingering issue of high cholesterol and cardiovascular disease. Founded by Ethan Weiss and led by CEO Josh Lehrer, Marea targets the ANGPTL4 gene, which has been linked to cardiometabolic disease but has not attracted much interest from the pharmaceutical industry due to safety concerns. The Third Rock-backed, 10-person startup plans to use its funding to pioneer the next frontier of cardiometabolic medicines and improve patient outcomes.
View original story
Similar markets
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%